New Data Confirm Clinical Efficacy and Strong Patient Preference for Onset Dermatologics (Formerly known as Onset Therapeutics) Foam Products

CUMBERLAND, R.I., Feb. 8, 2011 (GLOBE NEWSWIRE) -- Onset Dermatologics, a PreCision Dermatology company and an emerging leader in the development and commercialization of novel, patent-protected products for the treatment of skin disorders, today announced that several clinical posters about Onset Dermatologics' products were presented during the Annual Meeting of the American Academy of Dermatology in New Orleans, LA from February 4th - 8th. Two of the studies validated the company's HylatopicPlus™ Emollient Foam as an effective therapy for treating patients with atopic dermatitis and impaired skin barrier function. Two additional poster presentations confirmed the tolerability and patient preference for BenzEFoam® (benzoyl peroxide) Emollient Foam 5.3% for the treatment of acne.